Abstract:e16184 Background: Hepatocellular carcinoma (HCC) is often diagnosed at an advanced stage, leaving patients ineligible for surgery. Sorafenib is a first-line therapy, but disease progression still occurs in most patients within a year. Toripalimab, an immune checkpoint inhibitor has demonstrated promising efficacy and safety in various solid tumors, and its combination with Sorafenib may alter outcomes in HCC patients. This study aims to assess the safety and efficacy of Toripalimab plus Sorafenib for the treatment of advanced HCC. Methods: This is a single-arm, open-label, prospective phase II clinical trial (NCT04926532) for patients with unresectable HCC. Participants receive Toripalimab (240mg, iv, d1) and Sorafenib (400mg, bid, po, d1-21) every 3 weeks until disease progression or unacceptable toxicity occurs. The primary endpoints are objective response rate (ORR) evaluated with RECIST v1.1 and safety. Secondary endpoints include progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and duration of response (DOR). Exploratory endpoints comprise monitoring indicators for the efficacy and sensitivity of immunotherapy drugs. Results: As of January 17, 2023, 28 patients were enrolled, with a median age of 59.8 years and 85.7% were male. All patients had Child-Pugh A classification. The median follow-up time was 14.7 months (2.3-31.3). The distribution of patients by CNLC stage was as follows: Ib/IIa/IIb/IIIa/IIIb stage were 25.0%, 17.9%, 25.0%, and 32.1%, respectively. Among all patients, 6 (21.4%) had distant metastasis, 7 (25.0%) had portal vein tumor thrombus (PVTT), and 3 (10.7%) had hepatic vein invasion. The ORR was 35.7% and DCR was 71.4%. Of the 28 patients, 3 (10.7%) achieved complete response (CR), and 7 (25.0%) achieved partial response (PR). The median DOR was 2.7 months (95% CI: 0.9-16.9). The median PFS was 4.8 months (95% CI: 3.1-18.9), and the median OS was not reached (95% CI: NA-NA). 6 patients (21.4%) underwent surgical resection, and 3 of them (50.0%) experienced postoperative recurrence. The median PFS of patients who underwent surgery was 20.4 months (95% CI: 12.6-NA). 6 patients (21.4%) withdrew due to adverse events (AEs). Treatment-related adverse events (TRAEs) occurred in 26/28 patients (92.9%). Grade 1-2 TRAEs occurred in 10/28 patients (35.7%), Grade 3 TRAEs occurred in 11/28 patients (39.3%), and no grade 4-5 TRAEs were observed. This study is currently ongoing. Conclusions: Toripalimab combined with Sorafenib demonstrated encouraging efficacy and tolerable toxicity as a first-line option for patients with unresectable HCC, with some patients achieving tumor downstaging and surgical resection. This combination could be considered an optional regimen for the first-line treatment of unresectable HCC. Clinical trial information: NCT04926532 .

Efficacy and safety of bintrafusp alfa in two phase 1 expansion cohorts with advanced hepatocellular carcinoma

Efficacy and safety of bintrafusp alfa in 2 phase I expansion cohorts with advanced HCC

P5-5 Phase 2/3 Study of Bintrafusp Alfa with Gemcitabine Plus Cisplatin As First-Line Treatment of Biliary Tract Cancer

Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial

Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors

Phase 1 trial of first-line bintrafusp alfa in patients with locally advanced or persistent/recurrent/metastatic cervical cancer

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for recurrent/metastatic cervical cancer after platinum failure: primary results from a phase 2 study

Bintrafusp Alfa and Chemotherapy As First-Line Treatment in Biliary Tract Cancer: A Randomized Phase 2/3 Trial

Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, PD-L1–high advanced non-small cell lung cancer: a randomized, open-label, phase 3 trial

Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial

AB052. P-20. Phase 2, Open-Label Study of Second-Line M7824 Treatment in Patients with Locally Advanced or Metastatic Biliary Tract Cancer

947P the Efficacy and Safety of Cadonilimab Combined with Lenvatinib for First-Line Treatment of Advanced Hepatocellular Carcinoma: A Phase Ib/II Clinical Trial

Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A for Nonrandomized, Open-label, Phase II Trial

The efficacy and safety of toripalimab combined with sorafenib for unresectable hepatocellular carcinoma: An open-label, prospective, single-arm phase II study.

Bintrafusp alfa, an anti-PD-L1:TGF-β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer

A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma

A multicenter, open-label, multiple-dose Phase Ib/II study evaluating the safety and tolerability of CS3008 (BLU-554) in combination with CS1001 in subjects with locally advanced or metastatic hepatocellular carcinoma (HCC) Research

Safety and efficacy of combination of GT90001, an anti-activin receptor-like kinase-1 (ALK-1) antibody, and nivolumab in patients with metastatic hepatocellular carcinoma (HCC).